Trade this ETF at your broker
Fund size | EUR 8 m |
Total expense ratio | 0.59% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 29.21% |
Inception/ Listing Date | 4 April 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | HANetf |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | J.P. Morgan Administration Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | J.P. Morgan SE - Dublin Branch |
Revision Company | Ernst and Young |
Fiscal Year End | 31 March |
Swiss representative | Waystone Fund Services (Switzeland) SA |
Swiss paying agent | Helvetische Bank AG |
Tax data | Bundesanzeiger | |
Germany | Unknown | |
Switzerland | ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Schrodinger | 1.76% |
NeoGenomics | 1.73% |
Lantheus Holdings | 1.69% |
ACADIA Pharmaceuticals | 1.50% |
EXACT Sciences | 1.48% |
Arcturus Therapeutics | 1.47% |
Telix Pharmaceuticals | 1.46% |
Demant | 1.42% |
West Pharmaceutical | 1.39% |
10x Genomics | 1.39% |
YTD | +9.51% |
1 month | +0.36% |
3 months | +12.13% |
6 months | +7.68% |
1 year | +20.31% |
3 years | - |
5 years | - |
Since inception (MAX) | - |
2023 | - |
2022 | - |
2021 | - |
2020 | - |
Volatility 1 year | 29.21% |
Volatility 3 years | - |
Volatility 5 years | - |
Return per risk 1 year | 0.69 |
Return per risk 3 years | - |
Return per risk 5 years | - |
Maximum drawdown 1 year | - |
Maximum drawdown 3 years | - |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | - |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
Stuttgart Stock Exchange | EUR | W311 | - - | - - | - |
Frankfurt Stock Exchange | EUR | - | W311 GY WELLEUIV | W311.DE WELLEURINAV=SOLA | RBC Europe Ltd |
XETRA | EUR | W311 | WELLEUIV | WELLEURINAV=SOLA | RBC Europe Ltd |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 951 | 0.40% p.a. | Accumulating | Sampling |
L&G Healthcare Breakthrough UCITS ETF USD Acc | 64 | 0.49% p.a. | Accumulating | Full replication |
L&G Pharma Breakthrough UCITS ETF | 16 | 0.49% p.a. | Accumulating | Full replication |
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF | 15 | 0.59% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 6 | 0.35% p.a. | Accumulating | Full replication |